🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Looking forward to following along with all these amazing featured voices, especially my two good friends and fellow advocates Stacey Tinianov (she/her) MPH, BCPA and Kim Newcomer Thank you ASCO for including advocates in this group! #ASCO25

Excited for this interactive patient centric discussion tomorrow ❗️ Plan to deep dive into KRAS directed therapeutic approaches that are rapidly evolving ❗️ Manju George MVSc PhD Rectal Cancer Survivor Betsy Post A.n.n.

Ibrahim Halil SAHIN, MD Manju George MVSc PhD Rectal Cancer Survivor Betsy Post A.n.n. Here's another exciting option opening mid 2025!! VS-7375/ cetuximab with KRAS G12D patients!

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database buff.ly/YcE6i1K This study analyzed individual data from 48 randomized trials involving

On this #DIPG Awareness Day, I am thinking about all the children, adolescents and adults struck by this terrible brain cancer, and the urgent need to honor them by supporting scientific research towards a cure. #DIPGAwareness #ScienceMatters

Every year I add more ribbons to my ASCO badge but I will always be most proud of the one that says CANCER SURVIVOR! Beyond proud to attend the annual mtg as a passionate advocate ready to lend my voice & collaborate to ensure a better future for all #ASCO25 #crcsm #ayacsm SWOG Cancer Research Network

De-escalation of therapy in early stage rectal cancer. In this Ph3 RCT (n=364), chemoRT & local excision was non-inferior to TME for T2-3a/bN0 rectal cancer. Currently, NCCN guidelines recommend TNT for all T3+ rectal cancer - but some may not need doublet chemo or TME.

Tough news on HER3-DXd. But negative trials don't always mean failed drugs. As a patient and advocate, I understand why (toxicities, lack of OS - they matter). But, I also find myself asking, why DID it work for the people it helped? What about trial design? Prior treatment(s)?

The ASCO Ed Book is the highest-quality, peer-reviewed, free #oncology #MedEd ever. Whether or not you are attending #ASCO25, don’t miss out on this, #OncTwitter #MedTwitter, #MedStudentTwitter. Bookmark this tweet to keep the link handy: ascopubs.org/toc/edbk/curre… #OncoAlert

General request to all those in the molecular testing space. PLEASE stop combining MRD testing & MCED testing in presentations. While the science may be similar, the implementation & patient education is NOT. Also, please bring primary care in the room to discuss MCEDs #ASCO25

You don't see survival curves like this often in colorectal cancer, let alone for BRAF mutated CRC. And Median OS: 30.3 vs. 15.1 months. Wow. What a win for our patients! #ASCO25

Superstar Midhun Malla gives us a master class on ctDNA use in colorectal cancer! Wow. #ASCO25

#ASCO25 I have my own bias, but nothing beats the colorectal cancer sessions at the Arie Crown 👑 Theater. OncoAlert #HappeningNow BRAF, KRASG12C, MSI, EGFR, ctDNA and beyond.

1st line encorafenib + cetuximab + mFOLFOX6 vs SOC in BRAF V600E-mCRC 🔎BREAKWATER: PFS + updated OS #ASCO25 👉ORR 65 vs 37 vs 43 % 👉mPFS 12.8 vs 7.1 vs 6.9 mo 👉mOS 30.3 vs 15.1 vs 19.1 mo 👉AE ≥3 76% vs 58 vs 15.7% 🧐 Really effective, new SOC in 1st line ESMO - Eur. Oncology

✳️Unpowered, non-randomized, imbalanced on MRD volume and we don’t even know clinical characteristics of triplets vs doublet regimen‼️ So many caveats in the study to conclude Irinotecan does not work ‼️ This study was not designed to test or compare doublet vs triplet ❗️A

Dr. Strickler PhIb CodeBreak101 in 2L+ #KRASG12C MT #mCRC ➡️ n=40 at Soto 960 mg QD + standard dose FOLFIRI + pmab (50% had PD w/irino before) ORR 55% w/prior irino PD, PFS 8.2 mos, OS 15.6 mos. No new safety signals. PhIII underway CodeBreaK 301 #ASCO25 OncoAlert

#ASCO25 CAIRO-6 delivers the first phase 3 data for perioperative chemo in resectable colorectal peritoneal mets. CRS + HIPEC ± periop systemic therapy (N=358) 🔵 PFS: 14 vs 7 mo 🔵 DFS: 12 vs 7 mo 🔴 OS: 54 vs 45 mo (NS) 📊 3-yr OS: 54% vs 53% — no meaningful difference ❌ Did

🌟 proud mentor alert!! Mir Lim presenting her findings that complement activation signatures in CRC associate with BRAF V600E mutations and immune-suppressing myeloid cells - for CRC primary tumors and liver mets alike! Can we utilize this for design of new tx strategies in

#ASCO25 Checkpoint inhibitors rarely move the needle alone in MSS CRC—but with vilastobart (XTX101), that may be changing. 🧬 Tumor-activated, Fc-enhanced anti-CTLA-4 ➕ Atezolizumab in late-line, checkpoint-naïve MSS CRC (N=40) 💥 In NLM patients (n=11): 2 confirmed + 1

Exercizumab?!